| Alectinib Pharmacokinetic in Patients With NSCLC (NCT05713006) | Instituto Nacional de Cancerologia de Mexico | 2022-05-01 |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (NCT04432207) | Imugene Limited | 2020-11-30 |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) (NCT03532698) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2020-08-01 |
| Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC (NCT04699721) | Xiangya Hospital of Central South University | 2020-07-01 |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer (NCT03628144) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-01 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (NCT03611738) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-01 |
| Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer (NCT03396185) | Betta Pharmaceuticals Co., Ltd. | 2018-05-09 |
| A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer (NCT03472053) | BioMarck Pharmaceuticals, Ltd. | 2018-02-01 |
| Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy (NCT03302247) | Fox Chase Cancer Center | 2018-01-15 |
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC (NCT03543683) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2018-01-01 |
| Survival Prolongation by Rationale Innovative Genomics (NCT03386929) | Worldwide Innovative Network Association | 2017-11-29 |
| Immunotherapy by Nivolumab for HIV+ Patients (NCT03304093) | Intergroupe Francophone de Cancerologie Thoracique | 2017-10-19 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (NCT03288870) | Biocad | 2017-09-19 |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients (NCT03334071) | University Hospital Southampton NHS Foundation Trust | 2014-04-04 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy (NCT02035683) | National Cancer Institute, Naples | 2013-10-01 |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (NCT01798485) | Synta Pharmaceuticals Corp. | 2013-04-01 |
| Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial (NCT02176369) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2013-02-01 |
| MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer (NCT01656551) | National Cancer Institute, Naples | 2012-08-01 |
| A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (NCT01473563) | Eli Lilly and Company | 2011-12-01 |
| Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NCT01493011) | Xijing Hospital | 2011-11-01 |
| MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer (NCT01405586) | National Cancer Institute, Naples | 2011-03-01 |
| Phase II Avastin Trial for Stage IIIB/IV NSCLC (NCT00766246) | Pharmatech | 2008-10-01 |